Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CDCP1 is a novel marker for hematopoietic stem cells.

Tim Conze1, Reiner Lammers, Selim Kuci

  • 1Department of Internal Medicine II, Division of Hematology, Immunology, and Oncology, University of Tübingen, Tübingen, Germany.

Annals of the New York Academy of Sciences
|June 12, 2003
PubMed
Summary

Researchers identified CDCP1 as a novel marker for hematopoietic stem cells. This transmembrane protein is highly expressed on a subset of CD34(+) stem/progenitor cells in bone marrow.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer.

mAbs·2024
Same author

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent <i>In Vivo</i> Activities in Mouse Models of Hematological and Solid Tumors.

Journal of medicinal chemistry·2024
Same author

Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.

Frontiers in molecular medicine·2024
Same author

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease.

Journal of translational medicine·2024
Same author

Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs?

Journal of translational medicine·2024
Same author

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease.

Journal of translational medicine·2023

Area of Science:

  • Cell Biology
  • Hematology
  • Immunology

Background:

  • CDCP1 (CUB-domain containing protein 1) is a transmembrane protein.
  • CDCP1 mRNA shows high expression in lung and colon tumors and K562 cells.
  • The extracellular domain features three CUB domains, and the cytoplasmic region has a hexalysine stretch.

Purpose of the Study:

  • To develop monoclonal antibodies for analyzing CDCP1 protein expression.
  • To identify the cell types expressing CDCP1 in peripheral blood and bone marrow.
  • To investigate the potential of CDCP1 as a marker for hematopoietic stem cells.

Main Methods:

  • Overexpression of CDCP1 in NIH-3T3 cells for antibody generation.
  • Immunization of Balb/c mice and generation of hybridoma clones.

Related Experiment Videos

  • Multi-color flow cytometry analysis of peripheral blood and bone marrow cells.
  • Transplantation of purified CDCP1(+) cells into NOD/SCID mice.

    • Main Results:

    • Four monoclonal antibodies (CUB1-CUB4) were successfully generated against CDCP1.
    • CDCP1 protein was not detected on mature blood cells (lymphocytes, monocytes, granulocytes, erythrocytes, platelets).
    • CDCP1 is predominantly expressed on a subset of CD34(+) stem/progenitor cells in bone marrow.
    • Transplanted CDCP1(+) cells engrafted and showed multi-lineage differentiation potential.

    Conclusions:

    • CDCP1 is a novel marker for identifying hematopoietic stem cells.
    • CDCP1 expression is restricted to a specific population of stem/progenitor cells.
    • These findings have implications for stem cell research and potential therapeutic applications.